PerkinElmer (PKI) anticipates reported and organic revenue growth of 98% and 90%, respectively, for Q1

April 13, 2021 4:21 PM EDT
Get Alerts PKI Hot Sheet
Price: $139.44 -0.4%

EPS Growth %: +455.2%

Financial Fact:
Net income: 0.53

Today's EPS Names:
OR, OPEN, LPRO, More
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of 98% and 90%, respectively, for the first quarter ended April 4, 2021.

PerkinElmer’s strong revenue performance was driven by broad-based momentum across the portfolio. In total, non-COVID-19, or core, demand increased approximately 10% organically year-over-year, and COVID-19 related solutions contributed approximately $535 million of revenue in the first quarter.

PerkinElmer will release its first quarter 2021 financial results after market close on Tuesday, May 4, 2021. The Company will host a conference call the same day at 5:00 p.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Jamey Mock, senior vice president and chief financial officer, will host the conference call.

To access the call, please dial (720) 405-2250 prior to the scheduled conference call time and provide the access code 7294952. A live audio webcast of the call will also be available on the Investors section of the Company's Web site at www.perkinelmer.com.

A replay of the webcast will be available beginning at 7:00 p.m. ET, Tuesday, May 4, 2021 through the Investors section of the Company’s website at www.perkinelmer.com.

In addition, PerkinElmer announced today that Steve Willoughby will be named vice president of investor relations effective May 5, 2021. Mr. Willoughby will assume this role from Bryan Kipp, who has transitioned into the role of vice president and general manager of Life Sciences integration.

Steve Willoughby joins PerkinElmer from Cleveland Research Company (CRC), an independent equity and market research firm with an exceptional reputation for ground-level intelligence. Most recently, Mr. Willoughby served as partner and senior analyst at CRC, providing detailed research, analysis and financial models on the Life Sciences and Managed Care industries to institutional investors across the United States and Europe. In 2018, Thomson Reuters StarMine named Mr. Willoughby the number-one analyst in the Life Science tools sector.

PerkinElmer, Inc. and Subsidiaries

Reconciliation of GAAP to Non-GAAP Financial Measures

PKI
Three Months Ended
April 4, 2021
Organic revenue growth: Projected
Reported revenue growth

98%

Less: effect of acquisitions including purchase accounting adjustments
and impact of divested businesses and foreign exchange rates

8%

Organic revenue growth

90%

Non-COVID-19
Three Months Ended
April 4, 2021
Organic revenue growth: Projected
Reported revenue growth

18%

Less: effect of acquisitions including purchase accounting adjustments
and impact of divested businesses and foreign exchange rates

8%

Organic revenue growth

10%



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Guidance

Related Entities

Dividend, Earnings